Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform. News about RenovoRx often highlights progress in both its commercial activities and its clinical development programs.
Investors following RNXT news can expect regular updates on the commercialization of RenovoCath as a stand‑alone targeted drug‑delivery device, including adoption trends among cancer centers, repeat purchase orders, and the expansion of institutions approved to purchase the device. Company announcements also describe physician interest and growing clinical demand for localized, arterial drug‑delivery approaches in solid tumors.
Another major news theme is RenovoRx’s ongoing Phase III TIGeR‑PaC trial, which evaluates intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer. Press releases cover clinical milestones, pharmacokinetic and pharmacodynamic sub‑study results, and abstract acceptances and presentations at scientific meetings such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
RenovoRx news also includes updates on its post‑marketing observational registry study collecting real‑world safety and survival data in solid tumors, as well as its support of investigator‑initiated trials in borderline resectable and metastatic or oligometastatic pancreatic cancer. In addition, the company reports on corporate developments such as Scientific Advisory Board appointments, participation in investor and industry conferences, and capital markets activities disclosed in SEC filings.
For readers tracking RNXT, this news stream provides ongoing insight into how RenovoRx is advancing its TAMP platform, expanding RenovoCath’s commercial footprint, and generating clinical evidence around its drug‑device combination candidate IAG.
RenovoRx (Nasdaq: RNXT) will host its First Quarter 2026 financial results and business highlights conference call on May 14, 2026 at 4:30 pm ET. Management will discuss commercial momentum for RenovoCath, repeat orders, and updates on the Phase III TIGeR-PaC trial nearing full enrollment and on track for completion in H1 2026.
A replay will be available through May 28, 2026, and webcast details are on the company's Investor Relations site.
RenovoRx (Nasdaq: RNXT) announced that a pharmacokinetic and pharmacodynamic sub‑study from its Phase III TIGeR‑PaC trial was accepted for presentation at the 2026 ASCO Annual Meeting.
The abstract (E16463) compares intra‑arterial gemcitabine via RenovoCath (IAG) with IV gemcitabine, examining systemic drug/metabolite levels and correlation with CA 19‑9. Online publication is scheduled for May 21, 2026 at 5:00 PM ET, and the meeting runs May 29–June 2, 2026 in Chicago.
RenovoRx (Nasdaq: RNXT) presented clinical imaging data at the 2026 SIR meeting showing the TAMP therapy platform enables localized intra-arterial delivery of gemcitabine for locally advanced pancreatic cancer (LAPC).
Post-treatment FDG PET/CT showed dramatic reductions in tumor metabolic activity after eight cycles over two months, suggesting potential treatment response with reduced systemic toxicity and earlier detection of effect versus anatomy.
RenovoRx (Nasdaq: RNXT) announced a Notice of Allowance from the Japan Patent Office for a patent titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum,” strengthening protection for its RenovoCath dual-occlusion catheter and its Trans-Arterial Micro-Perfusion (TAMP) platform.
The allowed claims cover integrated imaging and pressure-sensing features for targeted infusion via the vasa vasorum; the company now reports 19 issued/allowed patents and 14 pending patents globally and is commercializing RenovoCath in the United States.
RenovoRx (Nasdaq: RNXT) was named one of Fast Company's World's Most Innovative Companies 2026, ranking #10 in the medical device category on April 1, 2026. The company highlights its FDA-cleared RenovoCath device and TAMP™ platform for targeted intra-arterial cancer therapy.
RenovoRx reported that 2025 was its first full year of revenue following the commercial launch of RenovoCath, and it estimates an initial U.S. peak annual device opportunity of ~$400 million, with multi-billion-dollar potential as indications expand.
RenovoRx (Nasdaq: RNXT) reported full-year 2025 results and a business update. RenovoCath generated $1.1 million in 2025 revenue. The company closed a private placement on March 20, 2026, raising $10 million gross (net $9.2 million) and has approximately $13 million cash on hand.
Clinical: Phase III TIGeR-PaC is on track with 104 randomized and 72 events; protocol requires 114 randomizations and 86 events for final analysis, with enrollment expected by mid-2026 and full data anticipated in 2027.
RenovoRx (Nasdaq: RNXT) reported a Phase III TIGeR-PaC enrollment milestone, surpassing 100 randomized patients (104 as of March 24, 2026) and remaining on track to complete enrollment in the first half of 2026. Final trial data are expected in 2027.
The trial requires 114 randomized patients and 86 events for final analysis; 72 events have occurred. Two pre-planned interim analyses led the independent DMC to recommend continuing the study. Select centers are using the RenovoCath-enabled TAMP therapy platform in parallel.
RenovoRx (Nasdaq: RNXT) closed an oversubscribed private placement, raising approximately $10 million gross on March 20, 2026. The financing included 10,638,790 shares issued at $0.938 per share and revenue milestone warrants for 5,319,392 shares (50% coverage).
The proceeds will fund RenovoCath commercialization and completion of the pivotal Phase III TIGeR-PaC trial, which the company expects to reach full enrollment by mid-2026 and report final data in 2027.
RenovoRx (Nasdaq: RNXT) will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026 at 4:30 p.m. ET. Management will discuss RenovoCath adoption at U.S. cancer centers, clinical and commercial momentum, and pipeline updates.
The company said the Phase III TIGeR-PaC trial remains on track to complete enrollment in the first half of 2026 with final data expected in 2027. RenovoRx will also review plans for post-marketing registry studies and investigator-initiated trials; a replay will be available through April 13, 2026.
RenovoRx (Nasdaq: RNXT) announced a definitive private placement expected to raise approximately $10 million in gross proceeds through the sale of ~10.64 million common shares and ~5.32 million milestone warrants.
Proceeds aim to accelerate RenovoCath commercialization, reduce cash burn, and fund full enrollment of the pivotal Phase III TIGeR-PaC trial by mid-2026, with results targeted in 2027. Closing expected March 20, 2026, subject to customary conditions.